Ticker LaunchFiled, not priced · BONS
Bonus Biogroup Ltd.
Bonus Biogroup Ltd. publicly filed a registration statement on Form F-1 on May 9, 2025 for a proposed initial public offering on Nasdaq Capital Market under the ticker BONS, and has not yet priced. Its latest amendment was filed on Mar 31, 2026. The filing shows a price range of $4.00–$6.00 per share. Underwriters named in the filing: D. Boral Capital.
Bonus Biogroup Ltd. is a clinical-stage biotechnology company developing tissue engineering and cell therapy products, including BonoFill, a personalized autologous bone graft, and MesenCure, an allogeneic cell therapy for inflammation and tissue damage.
- Status
- Filed, not priced
- Ticker
- BONS
- Exchange
- Nasdaq Capital Market
- Price range
- $4.00–$6.00
- First filed
- May 9, 2025
- Latest amendment
- Mar 31, 2026
- Underwriters
- D. Boral Capital
- Sector
- Biotech & pharma
More on this listing for subscribers
- Shares offered, over-allotment and shares outstanding after the offering
- Amendment history
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (F-1) first filed May 9, 2025
- Latest amendment Mar 31, 2026
- All filings on EDGAR CIK 1710531
Other companies in the IPO pipeline
- Neuro Spectrum Insights, Inc.Jun 20, 2025
- Ultra High Point Holdings LtdMay 20, 2025
- Uptrend Holdings LtdMay 20, 2025
- World Road Inc.May 16, 2025
- Zi Yun Dong Fang LtdMay 16, 2025
- HengHong Technology Inc.Mar 27, 2025